Introduction
The abuse of the illicit psychostimulant methamphetamine (METH) has reached epidemic proportions in the USA and throughout the world (Krasnova and Cadet, 2009 ). This is a growing public health disaster because chronic METH abuse is associated with serious health complications that include impairments in learning, memory, decision-making (Scott et al., 2007) and motor deficits (Caligiuri and Buitenhuys, 2005) in humans. In addition to these negative neuropsychiatric consequences, neuroimaging studies have found persistent decreases in the levels of dopamine transporters (DAT) and vesicular monoamine transporters 2 in the striatum and cortex (Sekine et al., 2001 (Sekine et al., , 2003 Volkow et al., 2001; Johanson et al., 2006; McCann et al., 2008) , indicating dopamine (DA) axonal damage in the brains of METH addicts.
Postmortem analyses have also detected decreases in tyrosine hydroxylase (TH), DAT and DA levels in the striatum of chronic METH abusers (Wilson et al., 1996; Moszczynska et al., 2004) . In addition to neurodegeneration of DA axons, METH addicts show loss of gray matter in the cortex, smaller hippocampus, and hypertrophy of the white matter, suggesting cell death and gliosis secondary to neuronal damage in the brain (Thompson et al., 2004) .
Evidence has accumulated to show that these drug-induced neuropathological changes might underlie deficits in cognitive behaviors in chronic METH abusers (Scott et al., 2007) . These ideas are further strengthened by data from animal studies showing that METH neurotoxicity is associated with impairments in motor learning (Chapman et al., 2001; Daberkow et al., 2005) , novel object recognition (Schroder et al., 2003; He et al., 2006; Belcher et al., 2008; Herring et al., 2008) and spatial memory acquisition (Friedman et al., 1998) in rodents. In addition to cognitive deficits, METH also causes disturbances in balance beam performance and increased latency in active avoidance task, suggesting appearance of motor impairments in drug-treated animals (Walsh and Wagner, 1992; however, see Timar et al., 2003) . Because the Methamphetamine (METH) is a psychostimulant that causes damage to dopamine (DA) axons and to non-monoaminergic neurons in the brain. The aim of the present study was to investigate short-and long-term effects of neurotoxic METH treatment on novelty-induced locomotor activity in mice. Male BALB/c mice, 12-14 weeks old, were injected with saline or METH (i.p., 7.5 mg/kg Â 4 times, every 2 h). Behavior and neurotoxic effects were assessed at 10 days, 3 and 5 months following drug treatment. METH administration caused marked decreases in DA levels in the mouse striatum and cortex at 10 days post-drug. However, METH did not induce any changes in novelty-induced locomotor activity. At 3 and 5 months after treatment METH-exposed mice showed significant recovery of DA levels in the striatum and cortex. In contrast, these animals demonstrated significant decreases in locomotor activity at 5 months in comparison to aged-matched control mice. Further assessment of METH toxicity using TUNEL staining showed that the drug induced increased cell death in the striatum and cortex at 3 days after administration. Taken together, these data suggest that delayed deficits in novelty-induced locomotor activity observed in METH-exposed animals are not due to neurodegeneration of DA terminals but to combined effects of METH and age-dependent dysfunction of non-DA intrinsic striatal and/or corticostriatal neurons.
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